Tempest Therapeutics (TPST) News
NASDAQ: TPSTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TPST news summary
We found 5 recent headlines mentioning Tempest Therapeutics (TPST): 1 in the past week and 4 in the past 30 days, most often from GlobeNewswire, Nasdaq. TPST is making an outsized move today, down 6.18% at $0.287, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Tempest Therapeutics, Inc. Receives Nasdaq Delisting Notification on November 17, 2026", was published by Nasdaq on Nov 20, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Tempest Therapeutics headlines
- Tempest Therapeutics, Inc. Receives Nasdaq Delisting Notification on November 17, 2026Tempest Therapeutics, Inc. received a delisting notification from the Listing Qualifications Staff of The Nasdaq Stock Market LLC on November 17, 2026, because the company did not meet the terms of…Nasdaq
- Tempest Reports Third Quarter 2026 Financial Results and Provides Business UpdateExclusively licensed Senlang’s CD7-Targeted lentiviral in vivo CAR-T platform following initial Phase 1 results with lead BCMA/GPRC5D candidate TPST-4903GlobeNewswire
- Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidatesGlobeNewswire
- Tempest Therapeutics Receives Nasdaq Notice of Bid Price Below $1.00On November 4, 2026, Tempest Therapeutics, Inc. received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the company that for the last 30 consecutive business…Nasdaq
- Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets ExpertiseBRISBANE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset…GlobeNewswire